Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003874 · ClinicalTrials.gov registry record · Phase 1
Monoclonal Antibody Therapy in Treating Patients With Lymphoma or Leukemia
A Phase 1 study, sponsored by Fred Hutchinson Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
NCT00003874 is a Phase 1 study that has completed, run by Fred Hutchinson Cancer Center.
The verdict
NCT00003874, a Phase 1 study, has completed, sponsored by Fred Hutchinson Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
Study Summary
RATIONALE: Monoclonal antibodies can locate cancer cells and either kill them or deliver cancer-killing substances without harming normal cells. PURPOSE: Phase I/II trial to study the effectiveness of monoclonal antibody therapy in treating patients who have lymphoma or leukemia.
Interventions
- PROCEDURE in vitro-treated peripheral blood stem cell transplantation
- BIOLOGICAL monoclonal antibody CD19
- BIOLOGICAL monoclonal antibody CD20
Trial Details
| Field | Value |
|---|---|
| Start Date | 1999-02 |
| Est. Completion | 2001-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00003874
The ClinicalTrials.gov registry entry for NCT00003874 describes a study currently listed as completed, categorized as Phase 1. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Fred Hutchinson Cancer Center, which has 483 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which in vitro-treated peripheral blood stem cell transplantation is the first listed.
NCT00003874 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00003874 about?
NCT00003874 is a clinical study titled "Monoclonal Antibody Therapy in Treating Patients With Lymphoma or Leukemia". RATIONALE: Monoclonal antibodies can locate cancer cells and either kill them or deliver cancer-killing substances without harming normal cells. PURPOSE: Phase I/II trial to study the effectiveness of monoclonal antibody therapy in treating patients who have lymphoma or leukemia.
What is the current status of trial NCT00003874?
This trial is currently completed. It is a Phase 1 study. The study started on 1999-02. Estimated completion is 2001-09.
What interventions are being tested in trial NCT00003874?
The interventions under investigation include: in vitro-treated peripheral blood stem cell transplantation (PROCEDURE), monoclonal antibody CD19 (BIOLOGICAL), monoclonal antibody CD20 (BIOLOGICAL).
Who is sponsoring clinical trial NCT00003874?
This trial is sponsored by Fred Hutchinson Cancer Center, which has 483 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.